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Background: Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications
including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface antigen (HBsAg) are the most
frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of
HBsAg in patients. However, the time course and duration of this effect is unclear. The objective of this
retrospective study was to clarify the frequency and duration of transient HBsAg positivity following vaccination
against HBV.
Methods: The electronic medical record at an academic tertiary care medical center was searched to identify all
orders for HBsAg within a 17 month time period. Detailed chart review was performed to identify all patients who
were administered HBV vaccine within 180 days prior to HBsAg testing and also to ascertain likely cause of weakly
positive (grayzone) results.
Results: During the 17 month study period, 11,719 HBsAg tests were ordered on 9,930 patients. There were
34 tests performed on 34 patients who received HBV vaccine 14 days or less prior to HBsAg testing. Of these
34 patients, 11 had grayzone results for HBsAg that could be attributed to recent vaccination. Ten of the
11 patients were renal dialysis patients who were receiving HBsAg testing as part of routine and ongoing
monitoring. Beyond 14 days, there were no reactive or grayzone HBsAg tests that could be attributed to recent
HBV vaccination. HBsAg results reached a peak COI two to three days following vaccination before decaying.
Further analysis of all the grayzone results within the 17 month study period (43 results out of 11,719 tests)
revealed that only 4 of 43 were the result of true HBV infection as verified by confirmatory testing.
Conclusions: Our study confirms that transient HBsAg positivity can occur in patients following HBV vaccination.
The results suggest this positivity is unlikely to persist beyond 14 days post-vaccination. Our study also
demonstrates that weakly positive HBsAg results often do not reflect actual HBV infection, underscoring the
importance of confirmatory testing. This study also emphasizes that vaccination-induced HBsAg positives occur
most commonly in hemodialysis patients.
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Hepatitis B virus (HBV) remains a common cause of
viral hepatitis, with possible long-term complications of
cirrhosis and hepatocellular carcinoma in patients who
develop chronic infection [1,2]. A variety of serological
and molecular-based laboratory assays are used to diag-
nose and manage HBV infection [2]. Hepatitis B surface
antigen (HBsAg) remains one of the most frequently
ordered tests. In both acute and chronic HBV infection,
HBsAg can be detected. HBsAg testing is commonly
used in the hemodialysis population to detect HBV in-
fection [3]. Patients who are documented as HBV-
positive utilize dedicated work areas and equipment to
avoid spread of HBV to other dialysis patients.
Vaccination to HBV has had a significant impact on
reducing infection [1,2]. However, one consequence of
HBV vaccination is the possibility of positive HBsAg
tests since HBV vaccine contains surface antigen [4,5].
In cases of recent vaccination, a positive HBsAg test can
lead to unnecessary confirmatory laboratory testing, with
added expense for the patient as well as the stress of a
false positive result. Unrecognized false positives can
lead to additional downstream effects such as reporting
to public health authorities and use of dedicated dialysis
equipment for renal failure patients. Positive HBsAg
results following HBV vaccination have been reported in
a variety of patient populations: neonates [6-10],
hemodialysis patients [4,11-13], blood donors [5,14,15],
and general adult patients [16-18]. The present study
aims to clarify the nature and duration of transient post-
vaccination positivity and how common vaccine-induced
positive results occur in an academic center population.
Methods
Setting
We conducted a retrospective analysis of electronic la-
boratory and medical records from a tertiary care aca-
demic medical center. The project had Institutional
Review Board approval from the University of Iowa. All
research carried out in human subjects was in compli-
ance with the Helsinki Declaration.
Selection of study subjects
The HBsAg testing used in this study was the cobasW
hepatitis B surface antigen assay (Roche Diagnostics, In-
dianapolis, IN, USA). The electronic medical record
(Epic, Epic Systems Inc., Madison, WI, USA) was
searched for the time period from April 2010 to Septem-
ber 2011 for patients who had HBsAg testing performed.
The inclusion criteria was having an HBsAg test ordered
and resulted. Instances where HBsAg testing was
ordered but unable to be performed due to interference
(e.g., hemolyzed specimen) or inadequate specimen were
excluded. By institutional policy for the hospital coreclinical laboratory, a reactive result for HBsAg was
defined by a Cut-Off Index (COI) of > 20. A weakly re-
active (“grayzone”) result was defined by COI ≥ 1 to ≤
20. All reactive and grayzone results were automatically
re-tested, with persistent grayzone results sent to a refer-
ence laboratory (ARUP Laboratories, Salt Lake City, UT,
USA) for confirmatory testing by HBsAg neutralization
assay. Chart review, including review of pharmacy
records, was performed for patients with grayzone and
reactive results. Two HBV vaccines were used during
the period of this retrospective study: Engerix-BW (at ei-
ther 20 mcg or 40 mcg dose, GlaxoSmithKline, Brent-
ford, Middlesex, United Kingdom) and a combined
hepatitis A/hepatitis B vaccine (TwinrixW, GlaxoSmithK-
line). Administration of these vaccines in both the in-
patient and outpatient setting was documented within
the electronic medical record medicine administration
record.
Data analysis
Statistical analyses were carried out in EP Evaluator re-
lease 9 (Data Innovations, South Burlington, VT, USA).
Results
HBsAg positivity due to recent vaccination
In the seventeen month time period of this retrospect-
ive study, there were 11,719 HBsAg tests ordered for
9,930 patients (with some patients being tested two or
more separate times during the time period of the
study), with a total of 43 grayzone and 268 reactive
results (see Figure 1). Thirty-four HBsAg tests were
performed on 34 different patients within 14 days of a
dose of Engerix-BW hepatitis B vaccine, with 24 of
these occurrences involving patients with chronic renal
failure who were tested prior to a hemodialysis treat-
ment (Additional File 1). Of these 34 tests, 11 were
resulted as grayzone; the remaining 23 were reported
as non-reactive (COI < 1). Patients with grayzone
results received the vaccine at a dose of either 20 mcg
(1 patient) or 40 mcg (10 patients). Demographic, med-
ical history, other laboratory testing, and nutritional
status of the 34 patients at the time of HBsAg testing
is detailed in Additional File 1.
In 10 of the 11 patients, the hepatitis B vaccine was
ordered by a different provider from the provider who
ordered the HBsAg test. These 10 patients were all
patients undergoing routine HBsAg surveillance testing
in the setting of receiving chronic hemodialysis for renal
failure, with all seven hemodialysis patients who had
HBsAg testing 5 days or less following a vaccine dose
having a grayzone reaction. One of the 11 patients had
hepatitis B vaccine and HBsAg testing both done as part
of the same outpatient encounter, with the vaccine
administered approximately 6 hours prior to the blood
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Figure 1 Flow diagram illustrating the derivation of the study sample.
Rysgaard et al. BMC Clinical Pathology 2012, 12:15 Page 3 of 6
http://www.biomedcentral.com/1472-6890/12/15draw for HBsAg testing. This patient received HBsAg
testing as part of medical testing prior to travel to an-
other country. For all 11 patients, there was no clinical
suspicion of active viral hepatitis; HBsAg testing was
done for screening purposes. Nine of the 12 patients
administered hepatitis B vaccine 6 days or less prior to
HBsAg testing had a grayzone reaction; in contrast, only
2 of 22 patients who were tested 7 to 14 days after a vac-
cine dose had a grayzone reaction (Additional File 1).
The longest interval between vaccination and grayzone
reaction was 12 days. All 11 patients with vaccine-
induced grayzone results had subsequent HBsAg per-
formed anywhere from 7 to 28 days later (and in many
cases multiple times thereafter); in each case, follow-up
testing was negative (Additional File 1). In addition, 9 of
the 11 patients had had prior HBsAg testing done any-
where from 12 days to 6 months prior to vaccination,
with negative HBsAg results in each case (Additional
File 1). None of the vaccine-induced HBsAg grayzone
reactions occurred in the pediatric population, despite
children under 18 years old comprising 28.1% of the
total HBsAg testing volume.Further analysis showed the COI for the HBsAg assay
reached a peak of 1.583 ± 0.464 at two to three days fol-
lowing vaccine administration before decaying to an
average of 0.578 ± 0.102 by day 14. After 5 days post-
vaccination, the COI was overall statistically not differ-
ent from the average COI of patients non-reactive for
HBsAg who had no prior vaccination (Figure 2). A dot
plot showing COI for the HBsAg test for all 34 patients
who received hepatitis B vaccine 14 days or less before
HBsAg testing is shown in Figure 3. There was one pa-
tient who had a positive HBsAg result 78 days after vac-
cination with Engerix-BW vaccine. However, this patient
had a documented history of chronic HBV infection and
was further found to have 49,000 IU/mL of hepatitis B
DNA on follow-up testing performed by a reference la-
boratory, demonstrating active HBV infection. With the
exception of this single patient, no reactive or grayzone
results were reported in patients who were tested for
HBsAg between 15 and 180 days following a Engerix-BW
vaccination dose (167 patients) or for two patients who
received a dose of the TwinrixW combined hepatitis A/
hepatitis vaccine within 14 days of HBsAg testing.
Figure 2 Cut-Off Index for the hepatitis B surface antigen test
for patients who received prior hepatitis B vaccination. The
Cut-Off Index (COI) for patients receiving vaccine 2–3 days and
4–5 days post-vaccine was statistically significant in comparison to
the COI of non-reactive hepatitis B surface antigen testing in
patients who did not receive prior vaccination (unpaired t-tests with
p < 0.01, indicated by **, and p < 0.05, indicated by *, respectively).
Figure 3 Dot plots of Cut-Off Index. The Cut-Off Index is plotted
for four populations: patients who received hepatitis B vaccine
7 days or less prior to HBsAg testing, patients who received vaccine
8–14 days prior to HBsAg testing, patients with grayzone HBsAg
reactions not attributed to vaccine or to actual hepatitis B virus
infection, and patients with grayzone reactions who appear to have
actual hepatitis B virus infection. The dashed line is at the Cut-Off
Index of 1 which divides non-reactive from grayzone.
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There were 32 patients with grayzone results for HBsAg
who had no history of HBV vaccine administration
within the prior 180 days. Demographic, medical history,
other laboratory testing, and nutritional status of these
32 patients at the time of HBsAg testing is detailed in
Additional File 2. Of these, 21 had a negative result by
confirmatory neutralization assay and can thus be defini-
tively considered false positives. These 21 patients were
from a fairly diverse patient population including preg-
nant women in first or second trimester (n = 7) and
patients with rheumatoid arthritis (n = 2), new onset
heart failure (n = 1), ulcerative colitis (n = 1), and pul-
monary hypertension (n = 1). Unlike the population of
patients who had suspected hepatitis B vaccine-induced
HBsAg grayzone results discussed above, only 2 of the
32 patients had chronic renal failure. Four patients with
grayzone results were verified by other laboratory testing
to have chronic HBV infection, which was also consist-
ent with clinical history and physical examination (Add-
itional File 2). Seven patients, including a one month old
infant with cholestatic jaundice, had a grayzone HBsAg
result but no neutralization assay follow-up; one of these
patients (25 year old male) was negative on a repeat
HBsAg test performed 5 days later. Chart review
revealed physician documentation of low clinical suspi-
cion of hepatitis B in all seven patients. Thus, out of the
total of 32 patients with grayzone results, only 4 had
clinical history and laboratory testing consistent with ac-
tual HBV infection (Additional File 2). The COI for the
HBsAg for the 4 patients with confirmed chronic HBV
infection and a grayzone reaction was 10.8 ± 7.0. The
COI for the remaining 28 patients with grayzone HBsAg
results was 2.8 ± 3.8. A dot plot showing COI for the
HBsAg test for all 32 patients with grayzone reactions
not associated with recent hepatitis B vaccination is
shown in Figure 3. For comparison, the average COI for
the 267 reactive HBsAg results was 3221 ± 706.
Discussion
The results of this study confirm that transient HBsAg
positivity can occur in patients who have recent HBV
vaccination. In our academic medical center population,
we found 11 cases out of 11,719 total tests (0.085%)
where vaccination caused weakly positive (grayzone)
HBsAg results. These 11 cases arose out of 34 instances
where HBV vaccine was administered within 14 days of
HBsAg testing. Ten of the 11 cases involved the higher
(40 mcg) of the two doses available for the Engerix-BW
vaccine.
In all 11 patients, HBsAg testing was for screening
purposes (either for dialysis patients or pre-travel labora-
tory tests) and not for work-up of clinically suspected
viral hepatitis infection. In addition, except for one
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the same outpatient visit, the other ten patients were all
hemodialysis patients who had the HBsAg test ordered
as part of ongoing surveillance and the HBV vaccine
administered during an outpatient visit to a different
provider (usually a primary care physician or registered
nurse practitioner). Our study is consistent with other
studies demonstrating hepatitis B vaccine-induced react-
ive HBsAg test in hemodialysis patients [4,11-13].
This study highlights why vaccine-induced positivity
for the HBsAg test is a persistent problem that is diffi-
cult to eliminate. One would predict that the challenge
is even greater if a patient is seen in two different health-
care systems that do not share a common electronic
medical record. In our own medical center, we have now
instituted a “Best Practice Alert” in our electronic med-
ical record that alerts the physician when a HBsAg test
is ordered within 14 days of a HBV vaccine order and
advises delaying HBsAg testing until at least 15 days
after vaccination.
The hemodialysis population is particularly challenging
with regard to HBsAg testing as patients often undergo
regular HBsAg testing and may be seen by other providers
for a variety of other medical issues. In addition, hemo-
dialysis patients tend to respond poorly to hepatitis B vac-
cines and thus frequently receive a higher dose of vaccine
than used in other patient populations. Hemodialysis
patients may even require additional doses of vaccine to
achieve adequate levels of antibodies against HBsAg [11].
There are two main limitations to the analysis pre-
sented in this paper. First, although pediatric patients 18
years old or less comprised 28.1% of the total HBsAg
tests, there were no pediatric patients that received
hepatitis B vaccine within 14 days of HBsAg testing.
Consequently, the results related to recent vaccine ad-
ministration are only applicable to adult patients. How-
ever, the sample size of this study exceeds that of
previous studies and contains a patient population that
likely is similar to that analyzed by clinical laboratories
at many academic medical centers, and has produced
results comparable to other similar studies of academic
medical center patient populations [4,11-13]. Second, al-
though nutritional status was not examined in detail, it
is likely that most patients in the study were well-
nourished and thus the findings are most applicable to
other well-nourished populations.
Our study also demonstrates that weakly positive
HBsAg results uncommonly reflect actual HBV infec-
tion. Of the overall 43 grayzone results out of 11,719
total tests, only 4 patients were found to have active
HBV infection by additional confirmatory laboratory
work-up, e.g., HBV DNA although it should be pointed
out that not all patients had detailed confirmatory work-
up performed. Reactive (not grayzone) HBsAg tests wereoften markedly higher than the upper limit of the gray-
zone (COI = 20) and generally had COIs of greater than
1,000. We believe our results should prompt caution in
interpretation of weakly positive HBsAg results, at least
for the Roche Diagnostics assay used, and also highlights
the importance of follow-up confirmatory testing to as-
certain true infection status and avoid the downstream
consequences of false positives.
Conclusions
Our study confirms that transient HBsAg positivity can
occur in patients following HBV vaccination, usually not
extending beyond 14 days post-vaccination. This study
also emphasizes that renal dialysis patients are a popula-
tion that vaccination-induced HBsAg positives most
commonly occurs. Decision support algorithms may be
effective in preventing attempts to order HBsAg testing
too soon following recent HBV vaccination.
Additional files
Additional file 1: Demographics, laboratory studies, and medical
histories of patients with HBsAg testing within 14 days of hepatitis
B vaccination.
Additional file 2: Demographics, laboratory studies, and medical
histories of patients with grayzone HBsAg results not attributed to
recent vaccination.
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